Literature DB >> 16243277

Therapeutic use of phage cocktail for controlling Escherichia coli O157:H7 in gastrointestinal tract of mice.

Yasunori Tanji1, Takuya Shimada, Hiroshi Fukudomi, Kazuhiko Miyanaga, Yutaka Nakai, Hajime Unno.   

Abstract

To investigate the therapeutical use of phage mixture for controlling gastrointestinal Escherichia coli O157:H7 cells, in vitro and in vivo experiments were conducted. Three phages, SP15, SP21, and SP22 were selected from 26 phage stock screened from feces of stock animals and sewage influent. Addition of single or binary phage to the E. coli cell batch-culture reduced the turbidity of the culture. However, reascend of the turbidity due to the appearance of phage resistance cell was observed. On the other hand, addition of three phage mixture (SP15-21-22) did not produce reascend of culture turbidity under aerobic condition. Under anaerobic condition, slight reascend of culture turbidity was observed after SP15-21-22 addition. Chemostat continuous culture was operated under anaerobic condition to optimize the titer of phage cocktail and frequency of the addition for controlling E. coli cells. Five-log decrease of E. coli cell concentration after addition of phage cocktail of 10(9) Plaque forming unit (PFU)/ml was observed. However, reascend of cell concentration was observed after 1 d incubation. Repeated addition of phage cocktail was effective to reduce the cell concentration. Suspension of phage cocktail in the buffer containing 0.25% CaCO3 neutralized 9 times much more buffer of pH 2. Based on this in vitro experiment, phage cocktail (SP15-21-22) suspended in the buffer containing 0.25% CaCO3 was orally administrated to the mice in which E. coli O157:H7 cells was administrated in 2-d advance. E. coli and phage concentration in the feces was monitored for 9 d after phage addition. High titer of phage was detected in the feces when the phage cocktail administrated daily. E. coli O157:H7 concentration in the feces has been reduced according to the time period. However, difference of E. coli concentration in the feces of mice administrates with phage and in the control mice without phage addition became slight after 9-d test period. High titer of the phage settled down in the gastrointestinal tracts and reduced the concentration of E. coli cell. Repeated oral administration of SP15-21-22 was effective for rapid evacuation of E. coli O157:H7 from the feces and gastrointestinal tract of mice.

Entities:  

Mesh:

Year:  2005        PMID: 16243277     DOI: 10.1263/jbb.100.280

Source DB:  PubMed          Journal:  J Biosci Bioeng        ISSN: 1347-4421            Impact factor:   2.894


  49 in total

1.  Genome sequencing and analysis of an Escherichia coli phage vB_EcoM-ep3 with a novel lysin, Lysep3.

Authors:  Meng Lv; Shuang Wang; Guangmou Yan; Changjiang Sun; Xin Feng; Jingmin Gu; Wenyu Han; Liancheng Lei
Journal:  Virus Genes       Date:  2015-04-05       Impact factor: 2.332

2.  Co-evolutionary dynamics of the bacteria Vibrio sp. CV1 and phages V1G, V1P1, and V1P2: implications for phage therapy.

Authors:  Camilo Barbosa; Patrick Venail; Angela V Holguin; Martha J Vives
Journal:  Microb Ecol       Date:  2013-09-08       Impact factor: 4.552

3.  Combined use of bacteriophage K and a novel bacteriophage to reduce Staphylococcus aureus biofilm formation.

Authors:  D R Alves; A Gaudion; J E Bean; P Perez Esteban; T C Arnot; D R Harper; W Kot; L H Hansen; M C Enright; A Tobias A Jenkins
Journal:  Appl Environ Microbiol       Date:  2014-08-22       Impact factor: 4.792

Review 4.  Phage Therapy in the Era of Synthetic Biology.

Authors:  E Magda Barbu; Kyle C Cady; Bolyn Hubby
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-10-03       Impact factor: 10.005

5.  Application of bacteriophages to control intestinal Escherichia coli O157:H7 levels in ruminants.

Authors:  Haiqing Sheng; Hannah J Knecht; Indira T Kudva; Carolyn J Hovde
Journal:  Appl Environ Microbiol       Date:  2006-08       Impact factor: 4.792

6.  Naturally resident and exogenously applied T4-like and T5-like bacteriophages can reduce Escherichia coli O157:H7 levels in sheep guts.

Authors:  Raul R Raya; Rebecca A Oot; Ben Moore-Maley; Serena Wieland; Todd R Callaway; Elizabeth M Kutter; Andrew D Brabban
Journal:  Bacteriophage       Date:  2011-01

7.  Isolation and characterization of a new T-even bacteriophage, CEV1, and determination of its potential to reduce Escherichia coli O157:H7 levels in sheep.

Authors:  Raul R Raya; Peter Varey; Rebecca A Oot; Michael R Dyen; Todd R Callaway; Tom S Edrington; Elizabeth M Kutter; Andrew D Brabban
Journal:  Appl Environ Microbiol       Date:  2006-09       Impact factor: 4.792

8.  Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections.

Authors:  Marine Henry; Rob Lavigne; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

9.  Orally administered P22 phage tailspike protein reduces salmonella colonization in chickens: prospects of a novel therapy against bacterial infections.

Authors:  Shakeeba Waseh; Pejman Hanifi-Moghaddam; Russell Coleman; Michael Masotti; Shannon Ryan; Mary Foss; Roger MacKenzie; Matthew Henry; Christine M Szymanski; Jamshid Tanha
Journal:  PLoS One       Date:  2010-11-22       Impact factor: 3.240

10.  Virulent bacteriophages can target O104:H4 enteroaggregative Escherichia coli in the mouse intestine.

Authors:  Damien Maura; Matthieu Galtier; Chantal Le Bouguénec; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.